JP2016512558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512558A5 JP2016512558A5 JP2016501870A JP2016501870A JP2016512558A5 JP 2016512558 A5 JP2016512558 A5 JP 2016512558A5 JP 2016501870 A JP2016501870 A JP 2016501870A JP 2016501870 A JP2016501870 A JP 2016501870A JP 2016512558 A5 JP2016512558 A5 JP 2016512558A5
- Authority
- JP
- Japan
- Prior art keywords
- butoxy
- tert
- acetic acid
- alkyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 54
- 125000000217 alkyl group Chemical group 0.000 claims 35
- -1 homopiperidinyl Chemical group 0.000 claims 30
- 125000001475 halogen functional group Chemical group 0.000 claims 20
- 125000001188 haloalkyl group Chemical group 0.000 claims 18
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000003302 alkenyloxy group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims 6
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000001425 triazolyl group Chemical group 0.000 claims 6
- 125000002393 azetidinyl group Chemical group 0.000 claims 5
- 125000002757 morpholinyl group Chemical group 0.000 claims 5
- 125000004193 piperazinyl group Chemical group 0.000 claims 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 4
- 208000037357 HIV infectious disease Diseases 0.000 claims 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 230000034303 cell budding Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- IXEPTGRMARFENT-HKBQPEDESA-N (2S)-2-[2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-6-methyl-4-(2-oxa-8-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-10-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C(F)C(C)=CC(CNC(=O)C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(C=4C=5N=CC=C6CCOC(C=56)=CC=4)C3=C2)=C1 IXEPTGRMARFENT-HKBQPEDESA-N 0.000 claims 1
- GXHHOTNIDWJTAS-XIFFEERXSA-N (2S)-2-[2-[4-[(4-fluorophenyl)methyl]pyrazol-1-yl]-6-methyl-4-(2-oxa-8-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-10-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C=4N=CC=C5CCOC(C=45)=CC=3)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1N(N=C1)C=C1CC1=CC=C(F)C=C1 GXHHOTNIDWJTAS-XIFFEERXSA-N 0.000 claims 1
- WAOBEXMKRVBRQA-YTTGMZPUSA-N (2S)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-6-methyl-4-(2-oxa-8-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-10-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C=4N=CC=C5CCOC(C=45)=CC=3)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(O1)=NC=C1CC1=CC=C(F)C=C1 WAOBEXMKRVBRQA-YTTGMZPUSA-N 0.000 claims 1
- SRRAXFGSMNTMDJ-YTTGMZPUSA-N (2S)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-6-methyl-4-(2-oxa-8-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-10-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C=4N=CC=C5CCOC(C=45)=CC=3)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(S1)=NC=C1CC1=CC=C(F)C=C1 SRRAXFGSMNTMDJ-YTTGMZPUSA-N 0.000 claims 1
- WLFXWNMWPYJDJD-PMERELPUSA-N (2S)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2H-chromen-6-yl)-2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound Cc1cc(CNC(=O)c2cc3c(-c4cc(F)c5OCCCc5c4C)c([C@H](OC(C)(C)C)C(O)=O)c(C)cn3n2)ccc1F WLFXWNMWPYJDJD-PMERELPUSA-N 0.000 claims 1
- JAORABFFBCNCEO-SANMLTNESA-N (2s)-2-[10-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-8-methylpyrido[1,2-b]indazol-9-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound O1CCCC2=C(C)C(C=3C4=C5C=CC=CC5=NN4C=C(C=3[C@H](OC(C)(C)C)C(O)=O)C)=CC(F)=C21 JAORABFFBCNCEO-SANMLTNESA-N 0.000 claims 1
- ULHWBJXCIRQVCU-SANMLTNESA-N (2s)-2-[2-(3-bromophenyl)-6-methyl-4-(4-methyl-4-prop-2-enoxypiperidin-1-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(C=3C=C(Br)C=CC=3)C=C2C=1N1CCC(C)(OCC=C)CC1 ULHWBJXCIRQVCU-SANMLTNESA-N 0.000 claims 1
- WRFUXBIIMNVOGZ-SNFDCCKOSA-N (2s)-2-[2-[3-[2-fluoro-3-methyl-6-[(2s)-pentan-2-yl]oxyphenyl]phenyl]-6-methyl-4-(4-methyl-4-propoxypiperidin-1-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1CC(OCCC)(C)CCN1C1=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2C1=CC(C=1C=C(C=CC=1)C=1C(=CC=C(C)C=1F)O[C@@H](C)CCC)=N2 WRFUXBIIMNVOGZ-SNFDCCKOSA-N 0.000 claims 1
- SLZYXZFOBJKSSS-SANMLTNESA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C(F)C(C)=CC(CNC(=O)C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(N4CCC(C)(C)CC4)C3=C2)=C1 SLZYXZFOBJKSSS-SANMLTNESA-N 0.000 claims 1
- CBDSJKSTELMHIB-NDEPHWFRSA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-[4-[(4-fluorophenyl)methyl]pyrazol-1-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(N3N=CC(CC=4C=CC(F)=CC=4)=C3)C=C2C=1N1CCC(C)(C)CC1 CBDSJKSTELMHIB-NDEPHWFRSA-N 0.000 claims 1
- NVXPQGHMBBOOKZ-MHZLTWQESA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(C=3OC(CC=4C=CC(F)=CC=4)=CN=3)C=C2C=1N1CCC(C)(C)CC1 NVXPQGHMBBOOKZ-MHZLTWQESA-N 0.000 claims 1
- KPPZTAGBWZZHPW-MHZLTWQESA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)C=C2C=1N1CCC(C)(C)CC1 KPPZTAGBWZZHPW-MHZLTWQESA-N 0.000 claims 1
- IMMDGLXLSLMURK-LJAQVGFWSA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-6-methyl-2-(3-pyridin-3-ylphenyl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(C=3C=C(C=CC=3)C=3C=NC=CC=3)C=C2C=1N1CCC(C)(C)CC1 IMMDGLXLSLMURK-LJAQVGFWSA-N 0.000 claims 1
- SVDHERPQDVBDEQ-NDEPHWFRSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C(F)C(C)=CC(CNC(=O)C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(C=4C(=C5NCCOC5=CC=4)Cl)C3=C2)=C1 SVDHERPQDVBDEQ-NDEPHWFRSA-N 0.000 claims 1
- YDLOXOOSLPJIAD-PMERELPUSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-2-[4-[(4-fluorophenyl)methyl]pyrazol-1-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4NCCOC4=CC=3)Cl)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1N(N=C1)C=C1CC1=CC=C(F)C=C1 YDLOXOOSLPJIAD-PMERELPUSA-N 0.000 claims 1
- WWVITSNUKPEINU-LJAQVGFWSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4NCCOC4=CC=3)Cl)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(O1)=NC=C1CC1=CC=C(F)C=C1 WWVITSNUKPEINU-LJAQVGFWSA-N 0.000 claims 1
- WCCOFXGPMUKLIR-LJAQVGFWSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4NCCOC4=CC=3)Cl)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(S1)=NC=C1CC1=CC=C(F)C=C1 WCCOFXGPMUKLIR-LJAQVGFWSA-N 0.000 claims 1
- BKIBDBSJHHXSKA-HKBQPEDESA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-6-methyl-2-(3-pyridin-3-ylphenyl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4NCCOC4=CC=3)Cl)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(C=1)=CC=CC=1C1=CC=CN=C1 BKIBDBSJHHXSKA-HKBQPEDESA-N 0.000 claims 1
- NVJFHRRQLBAVPZ-XIFFEERXSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-6-methyl-2-[3-(2-methylphenyl)phenyl]pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC1=CC=CC=C1C1=CC=CC(C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(C=4C(=C5NCCOC5=CC=4)Cl)C3=C2)=C1 NVJFHRRQLBAVPZ-XIFFEERXSA-N 0.000 claims 1
- FGHYDWDTGCEFGN-HKBQPEDESA-N (2s)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(O1)=NC=C1CC1=CC=C(F)C=C1 FGHYDWDTGCEFGN-HKBQPEDESA-N 0.000 claims 1
- YKGGXUFXZCSKHI-HKBQPEDESA-N (2s)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(S1)=NC=C1CC1=CC=C(F)C=C1 YKGGXUFXZCSKHI-HKBQPEDESA-N 0.000 claims 1
- DZVRFPSOOQHJFK-XIFFEERXSA-N (2s)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-6-methyl-2-(3-pyridin-3-ylphenyl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(C=1)=CC=CC=1C1=CC=CN=C1 DZVRFPSOOQHJFK-XIFFEERXSA-N 0.000 claims 1
- QETAKGCWTITPHK-DHUJRADRSA-N (2s)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-6-methyl-2-[3-(2-methylphenyl)phenyl]pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC1=CC=CC=C1C1=CC=CC(C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(C=4C(=C5CCCOC5=C(F)C=4)C)C3=C2)=C1 QETAKGCWTITPHK-DHUJRADRSA-N 0.000 claims 1
- ALLIZEAXNXSFGD-UHFFFAOYSA-N 1-methyl-2-phenylbenzene Chemical compound CC1=CC=CC=C1C1=CC=CC=C1 ALLIZEAXNXSFGD-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781764P | 2013-03-14 | 2013-03-14 | |
| US61/781,764 | 2013-03-14 | ||
| PCT/US2014/025525 WO2014159959A1 (en) | 2013-03-14 | 2014-03-13 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512558A JP2016512558A (ja) | 2016-04-28 |
| JP2016512558A5 true JP2016512558A5 (cg-RX-API-DMAC7.html) | 2017-03-09 |
Family
ID=50842317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501870A Pending JP2016512558A (ja) | 2013-03-14 | 2014-03-13 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9527842B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2970274B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016512558A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105189503B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2623904T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014159959A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015123230A1 (en) * | 2014-02-12 | 2015-08-20 | Bristol-Myers Squibb Company | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| WO2015126765A1 (en) | 2014-02-19 | 2015-08-27 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9193720B2 (en) | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| JP6579549B2 (ja) | 2014-05-16 | 2019-09-25 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する３環性複素環誘導体 |
| WO2016194806A1 (ja) | 2015-05-29 | 2016-12-08 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する含窒素３環性誘導体 |
| WO2017006261A1 (en) | 2015-07-06 | 2017-01-12 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| KR20180025926A (ko) | 2015-07-08 | 2018-03-09 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서의 피리딘-3-일 아세트산 유도체 |
| BR112018000253A2 (pt) | 2015-07-09 | 2018-09-04 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, método para tratar a infecção pelo hiv. |
| EP3319954A1 (en) | 2015-07-09 | 2018-05-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| AU2016306065A1 (en) | 2015-08-07 | 2018-03-01 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| JP2018522924A (ja) | 2015-08-10 | 2018-08-16 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのイミダゾピリジン大環状化合物 |
| AR105653A1 (es) | 2015-08-11 | 2017-10-25 | VIIV HEALTHCARE UK (Nº 5) LTD | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana |
| AU2016305339A1 (en) | 2015-08-12 | 2018-03-01 | VIIV Healthcare UK (No.5) Limited | 5-(n-fused tricyclic Aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of Human Immunodeficiency Virus replication |
| TW201718537A (zh) | 2015-08-12 | 2017-06-01 | Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物 |
| US10577353B2 (en) | 2015-08-12 | 2020-03-03 | VIIV Healthcare UK (No.5) Limited | 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| RU2018107928A (ru) | 2015-08-20 | 2019-09-20 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| LT3394033T (lt) | 2015-12-22 | 2021-03-10 | Incyte Corporation | Heterocikliniai junginiai, kaip imunomoduliatoriai |
| US20170320875A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017195113A1 (en) | 2016-05-11 | 2017-11-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3455214A1 (en) | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3455217A1 (en) | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HRP20221030T1 (hr) | 2016-06-20 | 2022-11-11 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| JP7149276B2 (ja) | 2016-12-22 | 2022-10-06 | インサイト・コーポレイション | Ｐｄ－ｌ１内在化誘導物質としてのテトラヒドロイミダゾ［４，５－ｃ］ピリジン誘導体 |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| BR112019012993A2 (pt) | 2016-12-22 | 2019-12-03 | Incyte Corporation | derivados de benzo-oxazol como imunomoduladores |
| TW201835068A (zh) | 2017-01-03 | 2018-10-01 | 英商Viiv醫療保健英國(No.5)有限公司 | 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物 |
| US20200016136A1 (en) | 2017-01-03 | 2020-01-16 | Viiv Healthcare Uk (No. 5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| SG11201909882SA (en) | 2017-04-24 | 2019-11-28 | Nantcell Inc | Targeted neoepitope vectors and methods therefor |
| MY210070A (en) | 2018-03-30 | 2025-08-25 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| PT3790877T (pt) | 2018-05-11 | 2023-05-10 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1 |
| WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| BR112022005826A2 (pt) | 2019-09-30 | 2022-06-21 | Incyte Corp | Compostos de pirido[3,2-d]pirimidina como imunomoduladores |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| HRP20120328T2 (hr) | 2007-11-15 | 2012-09-30 | Gilead Sciences | Inhibitori replikacije virusa humane imunodeficijencije |
| EP2574610A1 (en) | 2007-11-15 | 2013-04-03 | Gilead Sciences, Inc. | Inhibitors of human immonodeficiency virus replication |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| CA2705338A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| WO2009066228A1 (en) | 2007-11-23 | 2009-05-28 | Koninklijke Philips Electronics N.V. | Compartment |
| US8338441B2 (en) * | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2781780C (en) | 2009-12-23 | 2015-02-17 | Katholieke Universiteit Leuven | Novel antiviral compounds |
| MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
| NZ604716A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| US8633200B2 (en) * | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| AU2011330850B2 (en) | 2010-11-15 | 2016-01-28 | Viiv Healthcare Uk Limited | Inhibitors of HIV replication |
| MX2013005478A (es) * | 2010-11-15 | 2013-08-29 | Univ Leuven Kath | Compuestos heterociclicos condensados antivirales. |
| US8791108B2 (en) * | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
-
2014
- 2014-03-13 EP EP14727271.0A patent/EP2970274B1/en not_active Not-in-force
- 2014-03-13 ES ES14727271.0T patent/ES2623904T3/es active Active
- 2014-03-13 WO PCT/US2014/025525 patent/WO2014159959A1/en not_active Ceased
- 2014-03-13 CN CN201480027109.2A patent/CN105189503B/zh not_active Expired - Fee Related
- 2014-03-13 US US14/773,223 patent/US9527842B2/en not_active Expired - Fee Related
- 2014-03-13 JP JP2016501870A patent/JP2016512558A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512558A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512507A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512511A5 (cg-RX-API-DMAC7.html) | ||
| RU2420284C2 (ru) | Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| JP2016512825A5 (cg-RX-API-DMAC7.html) | ||
| JP2017526748A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501133A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528301A5 (cg-RX-API-DMAC7.html) | ||
| JP2016538313A5 (cg-RX-API-DMAC7.html) | ||
| NO20075682L (no) | Sammensetninger omfattende et oralt aktivt 1,2,4-oksadiazol for nonsense mutasjonsundertrykkelsesterapi | |
| JP2007519649A5 (cg-RX-API-DMAC7.html) | ||
| JP2017528494A (ja) | ｓＧＣ刺激剤 | |
| JP2016535795A5 (cg-RX-API-DMAC7.html) | ||
| RU2017107715A (ru) | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека | |
| RU2015120216A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2016506961A5 (cg-RX-API-DMAC7.html) | ||
| JP2015524841A5 (cg-RX-API-DMAC7.html) | ||
| JP2011513475A5 (cg-RX-API-DMAC7.html) | ||
| NO20091826L (no) | Fremgangsmater for dosering av oralt aktive 1,2,4-oksadiazol for nonsense mutasjonsuppresjonsterapi | |
| JP2014532754A5 (cg-RX-API-DMAC7.html) | ||
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич | |
| JP2018522927A5 (cg-RX-API-DMAC7.html) |